Are efficacy and safety of angiotensin receptor blockade modified by aspirin in patients with chronic heart failure : a cohort study from the Candesartan in Heart failure -- Assessment of Reduction in Mortality and morbidity ( CHARM ) programme?
There appears to be no significant modification of the benefit of candesartan on CV mortality and morbidity outcomes or safety by concomitant use of aspirin in patients with chronic HF.
Two novel class II associations are described in Mexicans with MS: DRB1*0403 and DRB1*0802. Both alleles share with DRB1*1501, valine-86 and negatively charged amino acids, in the DRB1-anchoring motif of pocket 4.